Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
16 Aprile 2024 - 1:30PM
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage
biotechnology company whose proprietary INTASYL™ siRNA gene
silencing technology is designed to make immune cells more
effective in killing tumor cells, today announced it is presenting
new data about its lead clinical candidate, PH-762, an INTASYL
compound. The data will be presented in three posters at the annual
meeting of the Society for Investigative Dermatology (SID) on May
16th in Dallas, Texas.
The titles of the three posters are:
- INTASYL Self-delivering RNAi: a Flexible Platform to Treat
Dermatological Malignancies
- INTASYL PH-762: Intratumoral Immunotherapy Targeting PD-1
- A Dose-Escalation Study of Intratumoral PH-762 Targeting PD-1
For Cutaneous Carcinoma
PH-762 is currently being studied in a US clinical trial to
assess safety and efficacy in specific skin cancers (NCT 06014086).
This open-label Phase 1 clinical study is designed to evaluate the
safety and tolerability of neoadjuvant use of intratumoral PH-762
in Stages 1, 2, and 4 cutaneous squamous cell carcinoma, Stage 4
melanoma, and Stage 4 Merkel cell carcinoma. Stages 1 and 2 cSCC
represent 77% of all new cSCC cases annually.
Presentation Details are as follows: |
|
|
|
1. |
Title: |
INTASYL self-delivering RNAi: A Flexible Platform to
Treat Dermatological Malignancies |
|
Abstract Number: |
575 |
|
Session Title: |
Pharmacology and Therapeutic Development |
|
Presenting Authors: |
Melissa Maxwell, Mary Spellman |
|
Session Date/Time: |
Thursday, May 16, 4:30-6:30pm |
|
Location: |
Trinity Exhibit Hall |
|
|
|
2. |
Title: |
INTASYL PH-762: Intratumoral immunotherapy targeting PD-1 |
|
Abstract Number: |
576 |
|
Session Title: |
Pharmacology and Therapeutic Development |
|
Presenting Authors: |
Melissa Maxwell, Mary Spellman |
|
Session Date/Time: |
Thursday, May 16, 4:30-6:30pm |
|
Location: |
Trinity Exhibit Hall |
|
|
|
3. |
Title: |
Intratumoral PH-762 targeting PD-1 for Cutaneous Carcinoma |
|
Abstract Number: |
283 |
|
Session Title: |
Clinical Research - Interventional Research |
|
Presenting Authors: |
Melissa Maxwell, Mary Spellman |
|
Session Date/Time: |
Thursday, May 16, 4:30-6:30pm |
|
Location: |
Trinity Exhibit Hall |
|
|
|
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage
biotechnology company whose proprietary INTASYL™ RNAi technology is
designed to make immune cells more effective in killing tumor
cells. INTASYL is the only self-delivering RNAi technology focused
on immuno-oncology therapeutics. INTASYL drugs precisely target
specific proteins that reduce the body’s ability to fight cancer,
without the need for specialized formulations or drug delivery
systems.
For additional information, visit the Company’s website,
www.phiopharma.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by words such as
"intends," "believes," "anticipates," "indicates," "plans,"
"expects," "suggests," "may," "would," "should," "potential,"
"designed to," "will," "ongoing," "estimate," "forecast," "target,"
"predict," "could" and similar references, although not all
forward-looking statements contain these words. These statements
are based only on our current beliefs, expectations and assumptions
and are subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict and many of which are
outside of our control. Our actual results may differ materially
from those indicated in the forward-looking statements as a result
of a number of important factors, including, but not limited to,
the impact to our business and operations by inflationary
pressures, rising interest rates, recession fears, the development
of our product candidates, results from our preclinical and
clinical activities, our ability to execute on business strategies,
our ability to develop our product candidates with collaboration
partners, and the success of any such collaborations, the timeline
and duration for advancing our product candidates into clinical
development, the timing or likelihood of regulatory filings and
approvals, the success of our efforts to commercialize our product
candidates if approved, our ability to manufacture and supply our
product candidates for clinical activities, and for commercial use
if approved, the scope of protection we are able to establish and
maintain for intellectual property rights covering our technology
platform, our ability to obtain future financing, market and other
conditions and those identified in our Annual Report on Form 10-K
and subsequent Quarterly Reports on Form 10-Q under the caption
"Risk Factors" and in other filings the Company periodically makes
with the SEC. Readers are urged to review these risk factors and to
not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. Phio does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release, except as
required by law.
Contact:Phio Pharmaceuticals
Corp.ir@phiopharma.com
PR ContactMichael AdamsBridge View
Mediaadams@bridgeviewmedia.com
Grafico Azioni Phio Pharmaceuticals (NASDAQ:PHIO)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni Phio Pharmaceuticals (NASDAQ:PHIO)
Storico
Da Feb 2024 a Feb 2025